Clinical Trial


Switch Study of Existing Atypical Antipsychotics to Bifeprunox


Brief description

The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.

Keywords

  •   Schizophrenia and Schizoaffective Disorder

Sponsored By

Solvay Pharmaceuticals

Unique Study ID

NCT00347425

Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

AstraZeneca
Hull, United Kingdom
Distance from Current Trial is 0 miles

No Investigator Listed

The University of Texas Health Science Center, Houston
HU3 2JZ, Hull, United Kingdom
Distance from Current Trial is 0 miles

No Investigator Listed

Janssen Research & Development, LLC
HU12 0PF, Hull, United Kingdom
Distance from Current Trial is 0 miles
View All